本帖最后由 老马 于 2012-1-13 21:20 编辑
8 v: V3 c, W4 A5 u, O2 F' i
S1 Y, t( @7 ]! V2 e7 n爱必妥和阿瓦斯丁的比较
$ J1 J: V/ Z! Z+ a/ |9 F6 o. r2 f9 c
" m! r! F- U4 d+ c% h1 @5 q' Z
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/# F% Q/ q0 V. S/ Q( W" C# C
: A. I8 e. L4 s- Z* G( \* W/ r: h
! u; j! S7 L' H* Nhttp://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/4 I V2 U7 g0 f3 q
==================================================6 P8 ], {* L. ?+ j4 B r( |/ z
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
$ f0 y% B5 D+ {- \( v7 k+ UPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.* l9 e( F* F; x& a3 c6 u" ~; |0 a9 m
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (～62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
& J; F* i0 v- a5 O- W7 N E; T$ S3 {
|
显身卡
